Thus, further investigations are required to understand and identify the pathways of dysregulated FGF21 signalling in obesity, which at the end will be important for the clinical translation of FGF21-based therapies. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.